WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
antibody-based anticancer products, today announced that the Company
will host a conference call at 8:00 a.m. ET on Friday, April 27, 2012,
to discuss ImmunoGen's financial results for the three-month period
ended March 31, 2012 — the third quarter of the Company's 2012 fiscal
year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-312-1388. Passcode is
5631072. The call also may be accessed through the Investor Information
section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through May 4, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now numerous TAP compounds in
clinical development with a wealth of clinical data reported.
ImmunoGen's collaborative partners include Amgen, Bayer HealthCare,
Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound
using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in
Phase III testing through the Company's collaboration with Genentech, a
member of the Roche Group. More information about ImmunoGen can be found
at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Kathryn Morris, 845-635-9828
Source: ImmunoGen, Inc.
News Provided by Acquire Media